A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Exclusion Criteria

• •Acute decompensated heart failure within 3 months prior to screening
• •SBP \<105 mmHg at screening or baseline.
• •Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 6 months prior to screening
• •Hemodynamically significant mitral and/or aortic valve disease, or any prior valve replacement, except mitral regurgitation secondary to LV dilation at screening
• •eGFR \<45 ml/min/1.73m2 at screening, as measured by the CKD-EPI formula
• •BMI \>40 kg/m2
• •Strong CYP3A4 inhibitors or inducers, sGC activators (vericiguat), PDE5 inhibitors, and nitroglycerin products
• •Women of childbearing potential
• •Further eligibility criteria might apply in alignment with the trial protocol.